A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

Effective treatments for alcohol dependence exist; however, they remain underused and are not effective, or suitable, for all ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

"In the case of oral semaglutide for overweight/obesity, it appears that 25 mg a day is that dose." The trial enrolled 243 participants with a BMI of at least 30, or 27 with a weight-related ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

In 2021, the FDA approved of another injectable semaglutide, Wegovy, for chronic weight management in adults with obesity/overweight and with at least one weight-related condition (such as high ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...